Piramal Pharma Reports Strong Financial Growth Amid Mixed Market Performance

Piramal Pharma has recently undergone a significant evaluation revision, reflecting a robust financial performance for the quarter ending March 2025. The company reported a remarkable growth in profit before tax less other income, reaching Rs 230.77 crore, which marks a substantial increase compared to the previous four-quarter average. Additionally, the operating profit to interest ratio has reached an impressive 5.41 times, indicating strong operational efficiency.
Net sales for the quarter hit a record high of Rs 2,754.07 crore, while the profit before depreciation, interest, and tax also peaked at Rs 560.99 crore. The net profit after tax stood at Rs 153.50 crore, translating to an earnings per share of Rs 1.16, both of which are the highest figures recorded by the company.

In terms of market performance, Piramal Pharma's stock has shown varied returns compared to the Sensex. Over the past year, the stock has delivered a return of 39.5%, significantly outperforming the Sensex's 13.08%. However, year-to-date figures indicate a decline of 21.54% for Piramal Pharma, contrasting with the Sensex's modest gain of 5.62%. This mixed performance highlights the company's potential amidst broader market trends.